Semaglutide leads to greater weight loss in women than men with heart failure
Semaglutide significantly improves symptoms in men and women with a common type of heart failure that has had few therapeutic options....
top of page
Browse by category
Search
Semaglutide changes the brain's response to sweet tastes in women with obesity
Semaglutide improved taste sensitivity, changed gene expression in the tongue that's responsible for taste perception, and changed the...
Study finds potential benefit of semaglutide in alcohol use disorders in real-world populations
Patients with obesity who received semaglutide had a 50%-56% lower risk for both the incidence and recurrence of alcohol use disorder...
Semaglutide may protect kidney function in individuals with a pre-existing kidney impairment
The latest analysis from the Semaglutide Effects on Heart Disease and Stroke in Patients with Overweight or Obesity Trial (SELECT) has...
MyPhenome Hungry Gut test identifies responders to semaglutide
The results of an independent study led by Mayo Clinic has found that the MyPhenome Hungry Gut test (Phenomix Sciences) can predict a...
Journal Watch 17/04/2024
Welcome to our weekly round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have...
Endoscopic sleeve gastroplasty more cost-effective than with semaglutide
An economic evaluation comparing endoscopic sleeve gastroplasty (ESG) with semaglutide for treating class II obesity has suggested ESG is...
CMS' semaglutide coverage expansion could save millions of lives
A group of 44 health care and advocacy organizations is urging the Centers for Medicare & Medicaid Services (CMS) to expand coverage and...
FDA approves Wegovy for CVD risk reduction in people with overweight or obesity and established cardiovascular disease
The FDA has approved a label expansion for Wegovy based on a supplemental New Drug Application (sNDA) for the indication of reducing...
FLOW trial: Semaglutide 1.0mg demonstrates 24% reduction in the risk of kidney disease-related events in T2DM and chronic kidney disease patients
Headline results from the kidney outcomes trial FLOW (Effect of Semaglutide Versus Placebo on the Progression of Renal Impairment in...
Browse by tag
bottom of page